MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control
June 28, 2022 07:00 ET
|
MeiraGTx
• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated • Significant improvements were demonstrated in...
MeiraGTx Reports First Quarter 2022 Financial and Operational Results
May 12, 2022 08:00 ET
|
MeiraGTx
- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients- Phase 1 AQUAx Study of AAV-hAQP1 for...
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
May 04, 2022 16:01 ET
|
MeiraGTx
LONDON and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that additional...
MeiraGTx Appoints Debra Yu, MD to Board of Directors
April 27, 2022 08:00 ET
|
MeiraGTx
LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment...
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences
April 19, 2022 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
March 10, 2022 08:00 ET
|
MeiraGTx
- Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing Patients- Received $30 Million Cash Milestone...
MeiraGTx Receives Clinical Development Milestone Payment from Janssen
January 27, 2022 08:30 ET
|
MeiraGTx
-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked...
MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
December 14, 2021 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast...
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 07, 2021 07:00 ET
|
MeiraGTx
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in two validated Patient Reported Outcome (PRO) measures6 of the 7 participants through 90-day assessments...
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation
November 29, 2021 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference...